Design, Synthesis, and Structure-Activity Relationship of Substrate Competitive, Selective, and in Vivo Active Triazole and Thiadiazole Inhibitors of the c-Jun N-Terminal Kinase

被引：78

作者：

De, Surya K. ^{[1
,2
]}

Stebbins, John L. ^{[1
,2
]}

Chen, Li-Hsing ^{[1
,2
]}

Riel-Mehan, Megan ^{[1
,2
]}

Machleidt, Thomas ^{[3
]}

Dahl, Russell ^{[1
,2
]}

Yuan, Hongbin ^{[1
,2
]}

Embadi, Aras ^{[1
,2
]}

Barile, Elisa ^{[1
,2
]}

Chen, Vida ^{[1
,2
]}

Murphy, Ria ^{[1
,2
]}

Pellecchia, Maurizio ^{[1
,2
]}

机构：

[1] Burnham Inst Med Res, Infect & Inflammatory Dis Ctr, La Jolla, CA 92037 USA

[2] Burnham Inst Med Res, Ctr Canc, La Jolla, CA 92037 USA

[3] Invitrogen Corp, Invitrogen Discovery Serv, Madison, WI 53719 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2009年 / 52卷 / 07期

关键词：

JNK; PEPTIDE; POTENT; IDENTIFICATION; PATHWAYS; DOCKING;

D O I：

10.1021/jm801503n

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We report comprehensive structure-activity relationship studies on a novel series of c-Jun N-terminal kinase (JNK) inhibitors. The compounds are substrate competitive inhibitors that bind to the docking site of the kinase. The reported medicinal chemistry and structure-based optimizations studies resulted in the discovery of selective and potent thiadiazole JNK inhibitors that display promising in vivo activity in mouse models of insulin insensitivity.

引用

页码：1943 / 1952

页数：10

共 30 条

[1] Identification of the critical features of a small peptide inhibitor of JNK activity [J].

Barr, RK ;

Kendrick, TS ;

Bogoyevitch, MA .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (13) :10987-10997

[2] SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase [J].

Bennett, BL ;

Sasaki, DT ;

Murray, BW ;

O'Leary, EC ;

Sakata, ST ;

Xu, WM ;

Leisten, JC ;

Motiwala, A ;

Pierce, S ;

Satoh, Y ;

Bhagwat, SS ;

Manning, AM ;

Anderson, DW .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (24) :13681-13686

[3] Therapeutic promise of JNK ATP-noncompetitive inhibitors [J].

Bogoyevitch, MA .

TRENDS IN MOLECULAR MEDICINE, 2005, 11 (05) :232-239

[4] Cell-permeable peptide inhibitors of JNK novel blockers of β-cell death [J].

Bonny, C ;

Oberson, A ;

Negri, S ;

Sauser, C ;

Schorderet, DF .

DIABETES, 2001, 50 (01) :77-82

[5]

*CAMBR CRYST DAT C, GOLD VERS 2 1

[6] A cytoplasmic inhibitor of the JNK signal transduction pathway [J].

Dickens, M ;

Rogers, JS ;

Cavanagh, J ;

Raitano, A ;

Xia, ZG ;

Halpern, JR ;

Greenberg, ME ;

Sawyers, CL ;

Davis, RJ .

SCIENCE, 1997, 277 (5326) :693-696

[7] Empirical scoring functions .1. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes [J].

Eldridge, MD ;

Murray, CW ;

Auton, TR ;

Paolini, GV ;

Mee, RP .

JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1997, 11 (05) :425-445

[8] Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase [J].

Gaillard, P ;

Jeanclaude-Etter, I ;

Ardissone, V ;

Arkinstall, S ;

Cambet, Y ;

Camps, M ;

Chabert, C ;

Church, D ;

Cirillo, R ;

Gretener, D ;

Halazy, S ;

Nichols, A ;

Szyndralewiez, C ;

Vitte, PA ;

Gotteland, JP .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (14) :4596-4607

[9] The neuroprotective action of JNK3 inhibitors based on the 6,7-dihydro-5H-pyrrolo[1,2-a]imidazole scaffold [J].

Graczyk, PP ;

Khan, A ;

Bhatia, GS ;

Palmer, V ;

Medland, D ;

Numata, H ;

Oinuma, H ;

Catchick, J ;

Dunne, A ;

Ellis, M ;

Smales, C ;

Whitfield, J ;

Neame, SJ ;

Shah, B ;

Wilton, D ;

Morgan, L ;

Patel, T ;

Chung, R ;

Desmond, H ;

Staddon, JM ;

Sato, N ;

Inoue, A .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (21) :4666-4670

[10] Selective interaction of JNK protein kinase isoforms with transcription factors [J].

Gupta, S ;

Barrett, T ;

Whitmarsh, AJ ;

Cavanagh, J ;

Sluss, HK ;

Derijard, B ;

Davis, RJ .

EMBO JOURNAL, 1996, 15 (11) :2760-2770

← 1 2 3 →